Shots:
- The EC has approved Nucala as an add-on maintenance treatment of adults with uncontrolled COPD characterised by raised blood eosinophils phenotype on a combination of an inhaled corticosteroid, a long-acting beta2-agonist (LABA), & a long-acting muscarinic antagonist
- Approval was based on the P-III (MATINEE) trial assessing Nucala (100mg, SC, Q4W; n=403) vs PBO (n=401) in addition to optimal inhaled triple therapy in COPD pts with type 2 inflammation
- Trial showed reduced annualized mod. or sev. exacerbation rates plus decreased annualised COPD exacerbations needing ED visits or hospitalization vs PBO, & results were published in NEJM in April 2025
Ref: GSKÂ | Â Image:Â GSK Â | Press Release
Related News: GSK’s Arexvy Receives the EC Approval to Prevent Respiratory Syncytial Virus (RSV) Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
